Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224507 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 4
- Study locations
NCT03224507: Completed Phase 2 study of Multiple Myeloma, sponsored by University of Alabama at Birmingham.
NCT03224507 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 123 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224507, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.
Primary Outcome
The primary endpoint of MRD(-) rate, or percentage of patients with MRD(-) remissions, will be estimated along with two-sided 95% confidence interval using Clopper-Pearson exact method. Simon's optimal two-stage design will be utilized in determining the rate of MRD(-) cases. MRD assessment will be done with ClonoSEQ to identify myeloma-specific sequences.
Conditions Studied
Interventions
- DRUG KRdD followed by auto-HCT
- DRUG KRdD only
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
Oregon
- Oregon Health and Science University - Portland
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Wisconsin
- University of Wisconsin, school of medicine and public health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 2 |
What the finished NCT03224507 record still lists
NCT03224507 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which KRdD followed by auto-HCT is the first listed.
NCT03224507 reports a single indexed study location in Alabama, Oregon, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03224507 about?
NCT03224507 is a clinical study titled "Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma". Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of compl...
What is the current status of trial NCT03224507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2018-03-14. Estimated completion is 2023-06-30.
What conditions does trial NCT03224507 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03224507?
The interventions under investigation include: KRdD followed by auto-HCT (DRUG), KRdD only (DRUG).
Who is sponsoring clinical trial NCT03224507?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224507 being conducted?
This trial has 4 study locations across Alabama, Oregon, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03224507's enrollment target sits among peer trials
123 149th of 438 higher than 289 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI